US20030143162A1 - Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics - Google Patents

Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics Download PDF

Info

Publication number
US20030143162A1
US20030143162A1 US10/151,701 US15170102A US2003143162A1 US 20030143162 A1 US20030143162 A1 US 20030143162A1 US 15170102 A US15170102 A US 15170102A US 2003143162 A1 US2003143162 A1 US 2003143162A1
Authority
US
United States
Prior art keywords
tobi
tobramycin
dose
patients
study
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/151,701
Other languages
English (en)
Inventor
Robert Speirs
Barbara Schaeffler
Peter Challoner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23123791&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20030143162(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority to US10/151,701 priority Critical patent/US20030143162A1/en
Publication of US20030143162A1 publication Critical patent/US20030143162A1/en
Priority to US10/743,529 priority patent/US6890907B2/en
Priority to US10/883,143 priority patent/US20040265241A1/en
Priority to US11/125,670 priority patent/US20050207987A1/en
Priority to US11/126,108 priority patent/US20050201947A1/en
Priority to US11/923,486 priority patent/US7825095B2/en
Priority to US12/884,505 priority patent/US20110005518A1/en
Priority to US13/295,228 priority patent/US8507454B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • the present invention relates to new and improved unit dose containers of aminoglycoside antibiotics, such as tobramycin, for delivery by aerosol inhalation, and to improved methods of treatment of susceptible acute or chronic endobronchial infections.
  • aminoglycoside antibiotics such as tobramycin
  • Aerosolized administration of aminoglycosides offers an attractive alternative, delivering high concentrations of antibiotic directly to the site of infection in the endobronchial space while minimizing systemic bioavailability (Touw D. J. et al., “Inhalation of antibiotics in cystic fibrosis,” Eur Respir J 8:1594-604 (1995); Rosenfeld M. et al., “Aerosolized antibiotics for bacterial lower airway infections: principles, efficacy, and pitfalls,” Clinical Pulmonary Medicine 4(2): 101-12 (1997)).
  • Tobramycin is commonly prescribed for the treatment of serious P. aeruginosa infections. It is an aminoglycoside antibiotic produced by the actinomycete, Streptomyces tenebrarius . Low concentrations of tobramycin ( ⁇ 4 ⁇ g/mL) are effective in inhibiting the growth of many Gram-negative bacteria and under certain conditions may be bactericidal (Neu, H. C., “Tobramycin: an overview,” J Infect Dis 134 , Suppl: S 3-19 (1976)). Tobramycin is poorly absorbed across mucosal surfaces, conventionally necessitating parenteral administration.
  • Tobramycin activity is inhibited by purulent sputum: high concentrations of divalent cations, acidic conditions, increased ionic strength and macromolecules that bind the drug all inhibit tobramycin in this environment. It is estimated that 5 to 10 times higher concentrations of tobramycin are required in the sputum to overcome these inhibitory effects (Levy J. et al., “Bioactivity of gentamicin in purulent sputum from patients with cystic fibrosis or bronchiectasis: comparison with activity in serum,” J Infect Dis 148(6):1069-76 (1983)).
  • aeruginosa strains highly resistant to tobramycin was comparable in the placebo and treatment groups.
  • the presence in the sputum of Gram-negative organisms other than P. aeruginosa intrinsically resistant to tobramycin occurred with equal frequency during administration of tobramycin or placebo (Ramsey B. et al., “Response to Letter to the Editor: Aerosolized tobramycin in patients with cystic fibrosis,” N Engl J Med 329:1660 (1993)).
  • a randomized, crossover study compared the ability of several nebulizers to deliver tobramycin by measuring peak sputum tobramycin concentrations in samples collected ten minutes after completion of the aerosol dose.
  • This study administered TOBI® tobramycin solution for inhalation, PathoGenesis Corporation, Seattle, Wash. (now Chiron Corporation, Emeryville, Calif.), containing 60 mg/mL tobramycin in 5 mL one quarter (1/4) normal saline, using the Pari® LC jet nebulizer, Pari Respiratory Equipment, Inc., Richmond, Va.
  • This delivery system was shown to deliver a mean peak sputum tobramycin concentration of 678.8 ⁇ g/g (s.d.
  • the one-way valves in the Pari® LC PLUS have been described as permitting the delivery of more drug than the Pari® LC jet nebulizer, while decreasing the potential for accidental spillage and allowing for the use of an expiratory filter.
  • mean peak sputum tobramycin concentrations achieved using the Pari LC PLUS jet nebulizer are significantly higher than those using the Pari® LC jet nebulizer as described in Eisenberg et al. (1997), supra.
  • Tobramycin-treated patients had an average 0.8 log 10 decrease in P. aeruginosa density from Week 0 to Week 20, compared with a 0.3 log 10 increase in placebo-treated patients (P ⁇ 0.001).
  • Tobramycin-treated patients had an average 1.9 log 10 decrease in P. aeruginosa density from Week 0 to Week 4, compared with no change in placebo-treated patients (P ⁇ 0.001).
  • a preservative-free, stable, and convenient formulation of tobramycin (TOBI® tobramycin solution for inhalation; 60 mg/mL tobramycin in 5 mL of 1/4 normal saline) for administration via jet nebulizer was developed by PathoGenesis Corporation, Seattle, Wash. (now Chiron Corporation, Emeryville, Calif.).
  • TOBI® tobramycin solution for inhalation 60 mg/mL tobramycin in 5 mL of 1/4 normal saline
  • the combination of a 5 mL BID TOBI dose (300 mg tobramycin) and the PARI LC PLUS/PulmoAide compressor delivery system was approved under NDA 50-753, December 1997, for the management of P. aeruginosa in CF patients, and remains the industry standard for this purpose.
  • a dose of less than about 4.0 ml of a nebulized aerosol formulation comprising from about 60 to about 200 mg/ml of an aminoglycoside antibiotic, such as tobramycin, in a physiologically acceptable carrier in a time period of less than about 10 minutes, more preferably less than about 8 minutes, and even more preferably less than about 6 minutes.
  • an aminoglycoside antibiotic such as tobramycin
  • the administered dose may be less than about 3.75 ml or 3.5 ml or less
  • the aminoglycoside antibiotic formulation may comprise from about 80 to about 180 mg/ml of aminoglycoside antibiotic or more preferably from about 90 to about 150 mg/ml of aminoglycoside antibiotic.
  • the present invention provides unit dose formulations and devices adapted for use in connection with a high efficiency inhalation system, the unit dose device comprising a container designed to hold and store the relatively small volumes of the aminoglycoside antibiotic formulations of the invention, and to deliver the formulations to an inhalation device for delivery to a patient in aerosol form.
  • a unit dose device of the invention comprises a sealed container, such as an ampoule, containing less than about 4.0 ml of an aminoglycoside antibiotic formulation comprising from about 60 to about 200 mg/ml of an aminoglycoside antibiotic in a physiologically acceptable carrier.
  • the sealed container is preferably adapted to deliver the aminoglycoside antibiotic formulation to a high efficiency inhalation device for aerosolization and inhalation by a patient.
  • the container of the unit dose device may contain less than about 3.75 ml, or 3.5 ml or less, of the aminoglycoside antibiotic formulation, and the aminoglycoside antibiotic formulation may comprise from about 80 to about 180 mg/ml, or from about 90 to about 120 mg/ml, of aminoglycoside antibiotic.
  • the present invention relates to a system for delivering an aminoglycoside antibiotic formulation to a patient in need of such treatment, comprising a unit dose device as described in detail above, comprising a container containing less than about 4.0 ml of an aminoglycoside antibiotic formulation comprising from about 60 to about 200 mg/ml of an aminoglycoside antibiotic in a physiologically acceptable carrier, and means for delivering the aminoglycoside antibiotic formulation from the unit dose device for inhalation by the patient in aerosolized form in less that 10 about minutes.
  • FIG. 1 is a graphical representation illustrating the mean relative changes in FEV 1 % predicted from before to 30 minutes after dosing with 300 mg tobramycin with a PARI LC PLUS jet nebulizer/PulmoAide compressor delivery system, or with 30, 60, or 90 mg tobramycin with an Aerodose breath actuated nebulizer, as described in Example 1;
  • FIG. 2 is a graphical representation showing sputum tobramycin concentrations by time from dosing by the tobramycin formulations of FIG. 1, as described in Example 1;
  • FIG. 3 is a graphical representation showing sputum maximum plasma concentrations (C max ) following dosing by the tobramycin formulations of FIG. 1, as described in Example 1;
  • FIG. 4 is a graphical representation showing sputum area under the plasma concentration time profile (AUC 0-8 ) following dosing by the tobramycin formulations of FIG. 1, as described in Example 1;
  • FIG. 5 is a graphical representation showing serum tobramycin concentrations by time following dosing by the tobramycin formulations of FIG. 1, as described in Example 1;
  • FIG. 6 is a graphical representation showing serum maximum plasma concentrations (C max ) following dosing by the tobramycin formulations of FIG. 1, as described in Example 1;
  • FIG. 7 is a graphical representation showing serum area under the plasma concentration time profile (AUC 0-8 ) following dosing by the tobramycin formulations of FIG. 1, as described in Example 1;
  • FIG. 8 is a graphical representation showing the mean recovery of tobramycin from urine 0-8,8-24 and 0-24 hours post dosing with the formulations of FIG. 1, as described in Example 1;
  • FIG. 9 is a graphical representation showing the mean nebulization time in minutes for dosing with the formulations of FIG. 1, as described in Example 1.
  • FIG. 10 is a graphical representation showing the average serum-time profiles of tobramycin after administration of 300 mg tobramycin (TOBI) and 420 mg tobramycin solution for inhalation (TSI), as described in Example 3.
  • FIG. 11 is a graphical representation showing the average sputum-time profiles of tobramycin after administration of 300 mg tobramycin (TOBI) and 420 mg tobramycin solution for inhalation (TSI), as described in Example 3.
  • TOBI 300 mg tobramycin
  • TSI 420 mg tobramycin solution for inhalation
  • methods are provided for the treatment of a patient in need of treatment, such as a patient suffering from an endobronchial P. aeruginosa infection, comprising administering to the patient for inhalation a relatively small volume of an aminoglycoside antibiotic formulation over a relatively short period of time.
  • This aspect of the invention is particularly suitable for formulation of concentrated aminoglycosides, such as tobramycin, for aerosolization by small volume, breath actuated, high output rate and high efficiency inhalers to produce a aminoglycoside aerosol particle size between 1 and 5 ⁇ m desirable for efficacious delivery of the aminoglycoside into the endobronchial space to treat susceptible microbial infections, such as Pseudomonas aeruginosa infections.
  • concentrated aminoglycosides such as tobramycin
  • the formulations preferably contains minimal yet efficacious amount of aminoglycoside formulated in smallest practical volume of a physiologically acceptable solution, for example an aqueous solution having a salinity adjusted to permit generation of aminoglycoside aerosol particles that are well-tolerated by patients but preventing the development of secondary undesirable side effects such as bronchospasm and cough.
  • a physiologically acceptable solution for example an aqueous solution having a salinity adjusted to permit generation of aminoglycoside aerosol particles that are well-tolerated by patients but preventing the development of secondary undesirable side effects such as bronchospasm and cough.
  • methods for the treatment of a patient in need of treatment, such as a patient suffering from an endobronchial P. aeruginosa infection, comprising administering to the patient for inhalation a dose of less than about 4.0 ml of a nebulized aerosol formulation comprising from about 60 to about 200 mg/ml of an aminoglycoside antibiotic in a time period of less than about 10 minutes.
  • the dose of the aerosol formulation is administered to the patient in less than about 8 minutes.
  • the dose of the aerosol formulation is administered to the patient in less than about 6 minutes.
  • the aerosol formulations administered in the practice of the invention may comprise from about 60 to about 200 mg/ml of aminoglycoside antibiotic. In other aspects of the invention, the aerosol formulations administered in the practice of the invention may comprise from about 80 to about 180 mg/ml of aminoglycoside antibiotic. In yet other aspects of the invention, the aerosol formulations administered in the practice of the invention may comprise from about 90 to about 150 mg/ml of aminoglycoside antibiotic.
  • substantially smaller volumes of aerosol formulation are administered to the patient, as compared with the conventional administration processes.
  • a dose of less than about 4.0 ml of a nebulized aerosol formulation is administered to the patient.
  • a dose of less than about 3.75 ml of a nebulized aerosol formulation is administered to the patient.
  • a dose of 3.5 ml or less of a nebulized aerosol formulation is administered to the patient.
  • the present invention relates to a system for delivering an aminoglycoside antibiotic formulation to a patient in need of such treatment, comprising a unit dose device as described in detail herein, comprising a container containing less than about 4.0 ml of an aminoglycoside antibiotic formulation comprising from about 60 to about 200 mg/ml of an aminoglycoside antibiotic in a physiologically acceptable carrier, and means for delivering the aminoglycoside antibiotic formulation from the unit dose device for inhalation by the patient in aerosolized form in less that 10 about minutes.
  • the antibiotic formulations are preferably administered with the use of an inhalation device having a relatively high rate of aerosol output.
  • Useful devices may also exhibit high emitted dose efficiency (i.e., low residual volume in the device).
  • emission may additionally be limited to periods of actual inhalation by the patient (i.e., breath actuated).
  • inhalation devices useful for use in the practice of the present invention will typically exhibit a rate of aerosol output of not less that about 4 ⁇ l/sec. In some cases, inhalation devices useful for use in the practice of the present invention will exhibit a rate of aerosol output of not less than about 5 ⁇ l/sec or even not less than about 8 ⁇ l/sec.
  • conventional air-jet nebulizers have a relatively low emitted dose efficiency and typically release about 55% (or less) of the nominal dose as aerosol
  • inhalation devices useful for use in the practice of the present invention may release at least about 75%, more preferably at least about 80% and most preferably at least about 85% of the loaded dose as aerosol for inhalation by the patient.
  • conventional air-jet nebulizers typically continually release aerosolized drug throughout the delivery period, without regard to whether the patient is inhaling, exhaling or in a static portion of the breathing cycle, thereby wasting a substantial portion of the loaded drug dose.
  • inhalation devices for use in the present invention will be breath actuated, and restricted to delivery of aerosolized particles of the aminoglycoside formulation to the period of actual inhalation by the patient.
  • One representative inhalation device meeting the above criteria and suitable for use in the practice of the invention is the AerodoseTM inhaler, available from Aerogen, Inc., Sunnyvale, Calif.
  • the Aerodose inhaler generates an aerosol using a porous membrane driven by a piezoelectric oscillator. Aerosol delivery is breath actuated, and restricted to the inhalation phase of the breath cycle, i.e., aerosolization does not occur during the exhalation phase of the breath cycle.
  • the airflow path design allows normal inhale-exhale breathing, compared to breath-hold inhalers. Additionally, the Aerodose inhaler is a hand-held, self-contained, and easily transported inhaler.
  • piezoelectric oscillator aerosol generators such as the AerodoseTM inhaler
  • other inhaler or nebulizer devices may be employed that meet the above performance criteria and are capable of delivering the small dosage volumes of the invention with a relative high effective deposition rate in a comparatively short period of time.
  • devices useful for delivering the concentrated aminoglycoside formulations of the invention include conventional air-jet nebulizers coupled with a compressor capable of higher than conventional output pressures.
  • Aminoglycoside antibiotics useful in the practice of the invention include, for example, gentamicin, amikacin, kanamycin, streptomycin, neomycin, netilmicin and tobramycin.
  • a presently particularly preferred aminoglycoside antibiotic for this purpose is tobramycin.
  • Formulations according to the invention typically contain from about 60 to about 200 mg, more preferably from about 80 to about 180, and most preferably from about 90 to about 120 mg of aminoglycoside per ml of solution.
  • the aminoglycoside antibiotic of the invention may be incorporated into sterile water or physiologically acceptable solution. Other components may be included in the formulation, as desired.
  • the aminoglycoside antibiotic of the invention is preferably formulated in a diluted physiological saline solution, such as in one quarter strength of normal saline, having a salinity adjusted to permit generation of tobramycin aerosol well-tolerated by patients but to prevent the development of secondary undesirable side effects such as bronchospasm and cough.
  • a diluted physiological saline solution such as in one quarter strength of normal saline, having a salinity adjusted to permit generation of tobramycin aerosol well-tolerated by patients but to prevent the development of secondary undesirable side effects such as bronchospasm and cough.
  • about 90 to about 120 mg of aminoglycoside antibiotic is dissolved in 1 ml solution of a diluted, typically quarter normal saline containing about 0.225% NaCl.
  • Quarter normal saline that is 0.225% of sodium chloride, is a presently preferred vehicle for delivery of aminoglycoside into endobronchial space.
  • tobramycin administered to the lungs by aerosolization result in maximization of sputum levels of tobramycin and in minimization of tobramycin serum levels.
  • administration of tobramycin by aerosolization has the advantage of reducing systemic toxicity while providing efficacious concentrations of tobramycin in the sputum.
  • the bronchial barrier restricts the movement of aerosolized tobramycin and prevents it from reaching high systemic levels.
  • unit dose formulations and devices are provided for administration of an aminoglycoside antibiotic formulation to a patient with an inhaler, in accordance with the methods of the invention as described supra.
  • Preferred unit dose devices comprise a container designed to hold and store the relatively small volumes of the aminoglycoside antibiotic formulations of the invention, and to deliver the formulations to an inhalation device for delivery to a patient in aerosol form.
  • unit dose containers of the invention comprise a plastic ampoule filled with an aminoglycoside antibiotic formulation of the invention, and sealed under sterile conditions.
  • the unit dose ampoule is provided with a twist-off tab or other easy opening device for opening of the ampoule and delivery of the aminoglycoside antibiotic formulation to the inhalation device.
  • Ampoules for containing drug formulations are well known to those skilled in the art (see, for example, U.S. Pat. Nos. 5,409,125, 5,379,898, 5,213,860, 5,046,627, 4,995,519, 4,979,630, 4,951,822, 4,502,616 and 3,993,223, the disclosures of which are incorporated herein by this reference).
  • the unit dose containers of the invention may be designed to be inserted directly into an inhalation device of the invention for delivery of the contained aminoglycoside antibiotic formulation to the inhalation device and ultimately to the patient.
  • a unit dose device comprising a sealed container containing less than about 4.0 ml of an aminoglycoside antibiotic formulation comprising from about 60 to about 200 mg/ml of an aminoglycoside antibiotic in a physiologically acceptable carrier, the sealed container being adapted to deliver the aminoglycoside antibiotic formulation to an inhalation device for aerosolization.
  • Suitable aminoglycoside antibiotics for use in connection with this aspect of the invention include those aminoglycoside antibiotics described in detail, supra.
  • the aminoglycoside antibiotic employed in the unit dose devices of the invention is tobramycin.
  • the unit dose devices of the invention contain less than about 3.75 ml of the aminoglycoside solution.
  • the unit dose devices of the invention contain 3.5 ml or less of the aminoglycoside solution.
  • the unit dose devices of the invention may contain an aminoglycoside antibiotic formulation comprising from about 80 to about 180 mg/ml of aminoglycoside antibiotic. In yet other aspects of the invention, the unit dose devices of the invention may contain an aminoglycoside antibiotic formulation comprising from about 90 to about 150 mg/ml of aminoglycoside antibiotic.
  • the physiologically acceptable carrier may comprise a physiological saline solution, such as a solution of one quarter strength of normal saline, having a salinity adjusted to permit generation of a tobramycin aerosol that is well-tolerated by patients, but that prevents the development of secondary undesirable side effects such as bronchospasm and cough.
  • a physiological saline solution such as a solution of one quarter strength of normal saline, having a salinity adjusted to permit generation of a tobramycin aerosol that is well-tolerated by patients, but that prevents the development of secondary undesirable side effects such as bronchospasm and cough.
  • the study was designed as an open label, randomized, multicenter, single dose, unbalanced, four treatment, three period crossover trial. Each patient was to receive three single doses of aerosolized antibiotic: the active drug control treatment during one treatment period and two of three experimental treatments during two additional treatment periods. Single dose administration during the three treatment periods was to occur at one-week intervals.
  • control delivery treatment PARI LC PLUS jet nebulizer+PulmoAide compressor
  • the duration of study participation for each patient was to be approximately five weeks including a brief (2 days to one week) screening period, three one-week treatment periods, and a one-week telephone follow-up period.
  • Each patient was to self-administer under research staff supervision a total of three single doses of aerosolized tobramycin during the study, one dose per crossover treatment period. Patients were to receive a single dose of the control delivery treatment during period 1 or period 2 of the three treatment periods. In addition, each patient was to receive single doses of two of the three experimental delivery treatments during the remaining two treatment periods. Control and experimental delivery treatments were specified as follows.
  • PARI LC PLUS jet nebulizer with PulmoAide compressor preservative free tobramycin 60 mg/mL (excipient 5 mL of 1/4 normal saline adjusted to a pH of 6.0 ⁇ 0.5); 300 mg in 5 mL.
  • Aerodose with a 3-4 ⁇ m mass medium diameter (MMD) aerosol particle size preservative free tobramycin 60 mg/mL (excipient 0.5 mL of 1/4 normal saline adjusted to a pH of 6.0 ⁇ 0.5); 30 mg in 0.5 mL;
  • Aerodose with a 3-4 ⁇ m MMD preservative free tobramycin 60 mg/mL (excipient 1.0 mL of 1 ⁇ 4 normal saline adjusted to a pH of 6.0 ⁇ 0.5); 60 mg in 1.0 mL;
  • Aerodose with a 3-4 ⁇ m MMD preservative free tobramycin 60 mg/mL (excipient 1.5 mL of 1 ⁇ 4 normal saline adjusted to a pH of 6.0 ⁇ 0.5); 90 mg in 1.5 mL.
  • a pharmacist or coordinator prepared the 30 mg dose of TOBI by drawing 0.5 mL of the 60 mg/mL TOBI formulation into a one-mL syringe. Each syringe was labeled with the patient identification number. Study drug was dispensed into the medication reservoir as indicated in the Aerodose directions for use. TOBI 60 mg and 90 mg doses were similarly prepared by drawing two and three 0.5 mL aliquots, respectively, from the TOBI ampoule into two and three one-mL syringes.
  • control delivery system PARI LC PLUS jet nebulizer
  • TOBI 300 mg control treatment
  • experimental delivery system Alodose inhaler
  • the control nebulizer the PARI LC PLUS jet nebulizer with DeVilbiss PulmoAide compressor, generates aerosol by air-jet shear.
  • Table 1 A detailed comparison of experimental and control devices is provided in Table 1.
  • Output rate 8.0 ⁇ L/sec 3.6 ⁇ L/sec Emitted dose 85% 57% Dose actuation Breath-actuated by On/off switch; when on, user inhalation medication aerosolized continuously Control of aerosol Breath actuated.
  • An Continuous aerosol output generation airflow sensor during both inhalation and system is used to exhalation limit aerosol generation to inhalation
  • User indicator lights Green LED flashing None for “device ready” and solid for “aerosolization” Red LED for “low battery”
  • Physical characteristics 3.3′′ ⁇ 2.6′′ ⁇ 1.1′′ 7.5′′ ⁇ 7.5′′ ⁇ 3.0′′
  • Power source Four AAA alkaline 115 VAC, 60 Hz batteries Power consumption 2.5 watts 90 watts (max.) Where used Fully portable Restricted to power outlets supplying 115 VAC, 60 Hz
  • Safety was assessed by monitoring the incidence of bronchospasm and by the quantitative change in pulmonary function (measured as change in FEV 1 % predicted), the incidence of treatment emergent adverse events, and the incidence of unusually high serum tobramycin results (>4 ⁇ g/mL), the significance of clinical laboratory test results, and the significance of change in clinical evaluation results.
  • bronchospasm airway reactivity
  • Bronchospasm was measured by the change in forced expiratory volume in 1 second [FEV 1 (liters)] from before dosing to 30 minutes after dosing during periods 1, 2, and 3.
  • the number and percent of patients who experienced predose to postdose decreases in FEV 1 (liters) that were ⁇ 10% and those that were ⁇ 20% were determined to assess the comparative incidence of bronchospasm among control and experimental treatments. Decreases in FEV 1 (liters) that were ⁇ 20% were considered clinically significant for the purposes of the study. Additionally, an acute decrease in FEV 1 (liters) ⁇ 30% from before to after treatment was considered a symptom of respiratory distress. In this event, continuation of the patient in the study was at the discretion of the investigator.
  • Norms have been developed for FEV 1 . These norms are commonly used in studies of pulmonary patients. This study employed the Knudson equations that use age, gender, and height to predict a patient's FEV 1 values as if the patient was free of pulmonary function disease. The actual FEV 1 value is divided by the normative value, and the resulting ratio is multiplied by 100 to produce a measure that represents percentage of predicted normal function, commonly called percent predicted. The transformation is:
  • FEV 1 % predicted ( FEV 1 actual value /FEV 1 normative value ) ⁇ 100
  • Relative change in FEV 1 % predicted is defined as the percent change from predose to 30 minutes postdose in FEV 1 % predicted and is calculated as:
  • FEV 1 % predicted [( FEV 1 (% predicted at 30 minutes postdose) ⁇ FEV 1 (% predicted at predose) )/ FEV 1 (% predicted at predose) ] ⁇ 100
  • Serum creatinine, blood urea nitrogen (BUN), and dipstick urine protein results were obtained from specimens drawn during screening and before dosing during treatment period 3. Urine dipstick testing was always performed on fresh specimens. Serum and urine specimens that needed to be retained at the site (e.g., those drawn after shipping pick-up hours or on Friday or Saturday) were frozen until shipment at the next earliest shipping time. Specimens were covered with dry ice for shipping.
  • Post treatment sputum specimens were collected following the normal saline gargle at 10 minutes and at 1, 2, 4, and 8 hours after completion of the aerosol drug administration for determination of sputum tobramycin concentrations. Sputum specimens were judged to be acceptable if collected within ⁇ 2 minutes of the scheduled 10-minute posttreatment collection time and within ⁇ 10 minutes of the scheduled 1-, 2-, 4-, and 8-hour collection times. After collection, specimens were immediately frozen for later determination of tobramycin concentrations in sputum. A minimum of 1 gram of sputum was required for analysis. Tobramycin concentrations in sputum (sputum LOQ 20.0 ⁇ g/gm) were measured by using HPLC.
  • Urine specimens were collected and combined in a 24-hour collection container during the 12 hours before treatment (-12-0 hour period) and during 0-8 hour and 8-24 hour collection periods after treatment according to instructions provided in the Study Manual. Total urine volume for the collection period was recorded, and a 10 mL aliquot from each urine collection was retained and frozen for later analysis of urine tobramycin concentration.
  • Urine tobramycin recovery was normalized for each collection period according to TOBI dose as follows.
  • % tobramycin excreted in urine [(urinary recovery in ⁇ g ⁇ 1000 ⁇ g/mg) ⁇ TOBI dose in mg] ⁇ 100%.
  • AUC 0- ⁇ Area under the concentration-time curve extrapolated to infinity
  • AUC 0- ⁇ AUC 0-last +C (last) ⁇ k el
  • AUC 0-last is area under the curve from predose through the last non-BQL time
  • C (last) is the last non-BQL posttreatment concentration result
  • k el is the elimination rate constant (terminal phase slope)
  • T 1/2 is the elimination half-life for the patient.
  • Relative systemic bioavailability was calculated based on serum AUC 0-8 values for control (TOBI 300 mg delivered by PARI LC PLUS nebulizer) and experimental (TOBI 30 mg, 60 mg, and 90 mg delivered by Aerodose inhaler) groups as follows.
  • Enrolled patients had documented laboratory (sweat chloride ⁇ 60 mEq/L by quantitative pilocarpine iontophoresis test (QPIT) and/or genotype with 2 identifiable mutations) and clinical evidence consistent with a diagnosis of cystic fibrosis.
  • Patients met all inclusion and exclusion criteria except for one patient whose pulmonary function entrance requirement (FEV 1 ⁇ 40% of predicted based on gender, age, and height) was waived (the patient's screening FEV 1 % predicted was 39.87%).
  • the average FEV 1 % predicted of all randomized patients was 66.4% at screening with a range from approximately 40% to 116%.
  • the study compared the rate of occurrence of bronchospasm (airway reactivity) between control and experimental delivery systems.
  • the occurrence of bronchospasm was determined quantitatively based on the percent change in FEV 1 (liters) from before dosing to 30 minutes after dosing in each of the 3 treatment periods.
  • predose to postdose reductions in FEV 1 (liters) ⁇ 10% and ⁇ 20% were defined as bronchospasm; reductions in FEV 1 (liters) ⁇ 20% were considered clinically significant.
  • Bronchodilator doses were to be administered 15 to 60 minutes prior to study treatments.
  • Treatment-emergent adverse events occurred in all treatment groups regardless of causality. The most common treatment-emergent experiences were associated with Respiratory and Body as a Whole systems. The most common individual events were cough increased, rhinitis, sputum increased, asthma, chest pain, and headache. These events were also common to the patient's pretreatment symptoms reflecting the patients underlying disease. For the majority of treatment-emergent adverse events, there were no meaningful differences between TOBI doses or between the PARI LC PLUS nebulizer and the AeroDoseTM inhaler.
  • SAEs serious adverse events
  • a single completing patient provided no sputum pharmacokinetic data for the TOBI 60 mg treatment.
  • One patient had missing sputum samples from 10 minutes through 8 hours after TOBI 60 mg treatment. After the database was locked, the missing sputum concentration results were located. Sputum tobramycin concentrations at 10 minutes and 1, 2, 4, and 8 hours were 0.82 ⁇ g/gm, BQL, 0.0, 0.0, and 0.0, respectively.
  • the database was not subsequently unlocked to add these data, since the inclusion of these values would have had minimal impact on estimation and analyses of pharmacokinetic parameters.
  • AeroDoseTM inhaler mean sputum tobramycin concentrations increased with increasing TOBI dose at each measurement time during the 8-hour postdose period.
  • Mean sputum concentrations for the TOBI 90 mg treatment with the AeroDoseTM inhaler were similar throughout the 8-hour period to those obtained for the TOBI 300 mg treatment with the PARI LC PLUS nebulizer.
  • C max maximum plasma concentrations
  • AUC 0-8 area under the plasma concentration time profile
  • C max and AUC 0-8 were statistically significant (p ⁇ 0.001) with no evidence of period or carryover (treatment by period interaction) effects.
  • AeroDoseTM inhaler was more efficient, regardless of TOBI dose, than the PARI LC PLUS nebulizer based on dose normalized sputum C max and AUC 0-8 results.
  • Dose normalized means for these pharmacokinetic parameters were similar among AeroDoseTM treatments but approximately 3-fold higher than the dose normalized results after TOBI 300 mg delivered by the PARI LC PLUS nebulizer (see Table 5).
  • T max in Table 5 above The time to maximum sputum tobramycin concentrations (T max in Table 5 above) was similar for all treatment groups and averaged between 0.24 and 0.38 hours for AeroDoseTM doses compared to 0.26 hours for the TOBI 300 mg treatment using the PARI LC PLUS. Elimination half-life (median T 1/2 in Table 5) was also similar among AeroDoseTM treatments, averaging 1.60 to 2.06 hours, compared to 1.71 hours for TOBI 300 mg.
  • Table 6 also identifies predose serum specimens for periods 2, 3, or both that had measurable tobramycin in 4 of the 5 patients. These findings are also reflected in non-zero mean amounts of predose tobramycin concentrations in periods 2 and 3. Three of the 5 patients exhibited measurable serum tobramycin after having received TOBI 300 mg during the immediately preceding study period.
  • Aerodose inhaler was more efficient, regardless of TOBI dose, than the PARI LC PLUS nebulizer based on dose normalized sputum C max and AUC 0-8 results.
  • Dose normalized means for these pharmacokinetic parameters were similar among Aerodose treatments but approximately 3-fold higher than the dose normalized results after TOBI 300 mg delivered by the PARI LC PLUS nebulizer (Table 7).
  • T max (Table 7) was similar for the four treatments, averaging between 0.98 and 1.14 hours for Aerodose treatments and 1.05 hours for the TOBI 300 mg treatment using the PARI LC PLUS.
  • Median T 1/2 ranged from 2.73 to 4.27 hours among the Aerodose dose levels, compared to 3.14 hours for TOBI 300 mg using the PARI LC PLUS nebulizer.
  • Median T 1/2 results using the Aerodose inhaler appeared to decrease with increasing TOBI dose, but this was considered an artifact related to greater frequency of missing T 1/2 values (due to more BQL results) at lower TOBI dose levels.
  • Table 8 shows that measurable urine tobramycin was recovered before dosing in periods 2, 3, or both for all 10 patients.
  • Sputum tobramycin concentrations throughout the 8-hour sampling period after dosing increased with increasing TOBI dose through 90 mg delivered by the Aerodose inhaler, but results for TOBI 90 mg and TOBI 300 mg delivered by the PARI LC PLUS nebulizer did not differ substantially or consistently. Sputum tobramycin results were highly variable, with coefficients of variation approaching or exceeding 100% for each treatment at all time points. On average, sputum concentrations reached their maximum at 10 minutes after each of the 4 treatments. By 2 hours after TOBI 30 mg and by 8 hours after TOBI 60 mg, 90 mg, and 300 mg, sputum concentrations were below the lower limit of quantifiability (LOQ) in at least half of the patients.
  • LOQ lower limit of quantifiability
  • Serum tobramycin concentrations also increased with increasing TOBI dose at each time during the 8-hour posttreatment observation period. Mean serum tobramycin concentrations reached their maximum at one hour after each treatment. By 4 hours after TOBI 30 mg and by 8 hours after TOBI 60 mg and TOBI 90 mg, serum concentrations were below LOQ in at least half of the patients. More than half of the TOBI 300 mg patients remained above the serum LOQ at 8 hours posttreatment.
  • Serum AUC (0- ⁇ ) was not analyzed statistically due to high variability but generally appeared to increase as the TOBI dose increased.
  • the Aerodose inhaler substantially reduced the time required for nebulization of all three dose levels (30 mg, 60 mg, and 90 mg) of TOBI compared to the nebulization time for the approved TOBI 300 mg delivery system using the PARI LC PLUS jet nebulizer. Average nebulization times were 2.8, 5.4, and 8.0 minutes using the Aerodose inhaler to deliver TOBI 30 mg, 60 mg, and 90 mg, respectively vs. 17.7 minutes using the PARI LC PLUS nebulizer to deliver TOBI 300 mg.
  • the Aerodose inhaler therefore cut nebulization time of the TOBI 90 mg dose by more than 50% compared to the PARI LC PLUS nebulizer in the present study, and nebulization times for lower TOBI doses were reduced by even greater amounts.
  • TOBI 90 mg (but not TOBI 60 mg or TOBI 30 mg) delivered by the Aerodose inhaler achieved similar actual pulmonary deposition, systemic absorption, and urinary recovery of tobramycin as that achieved by administration of the TOBI 300 mg dose delivered by the PARI LC PLUS nebulizer.
  • the Aerodose inhaler was substantially more efficient than the PARI LC PLUS nebulizer in the delivery of aerosolized tobramycin to the lungs and to the systemic circulation.
  • Pulmonary deposition of tobramycin was measured by determination of sputum tobramycin concentrations and by calculation of sputum pharmacokinetic parameters. Maximum sputum tobramycin concentrations were reached by 10 minutes after administration of each treatment, and concentrations were below the LOQ in half or more of the patients at 2 hours after TOBI 30 mg and at 8 hours after TOBI 60 mg, 90 mg, and 300 mg.
  • Dose-normalized sputum C max was 10.97, 9.63, and 10.64 ( ⁇ g/gm)/mg for TOBI 30 mg, 60 mg, and 90 mg delivered by Aerodose inhaler, respectively, compared to 3.29 ( ⁇ g/gm)/mg for TOBI 300 mg delivered by PARI LC PLUS.
  • dose-normalized sputum AUC 0-8 was 12.03, 13,41, and 14.17 [hr ⁇ g/gm]/mg for TOBI 30 mg, 60 mg, and 90 mg delivered by Aerodose inhaler, respectively, compared to 4.90 [hr ⁇ g/gm]/mg for TOBI 300 mg delivered by PARI LC PLUS.
  • present serum tobramycin results demonstrated that TOBI 90 mg delivered by the Aerodose inhaler were similar (AUC 0-8 ) or nearly similar (C max ) to those obtained after TOBI 300 mg delivered by the PARI LC PLUS nebulizer in the present study and in the prior pivotal studies supporting the TOBI commercial product.
  • Present serum results also demonstrated that the experimental Aerodose inhaler was substantially more efficient, regardless of TOBI dose, in delivery of aerosolized tobramycin to the systemic circulation than the PARI LC PLUS jet nebulizer.
  • Dose-normalized serum C max was 0.0127, 0.0116, and 0.0106 ( ⁇ g/mL)/mg for TOBI 30 mg, 60 mg, and 90 mg delivered by Aerodose inhaler, respectively, compared to 0.0037 ( ⁇ g/mL)/mg for TOBI 300 mg delivered by PARI LC PLUS.
  • dose-normalized serum AUC 0-8 was 0.0478, 0.0496, and 0.0438 [hr ⁇ g/mL]/mg for TOBI 30 mg, 60 mg, and 90 mg delivered by Aerodose inhaler, respectively, compared to 0.0166 [hr ⁇ g/mL]/mg for TOBI 300 mg delivered by PARI LC PLUS.
  • the greater efficiency of the Aerodose inhaler observed in present serum tobramycin results is consistent with greater efficiency and less wastage of the tobramycin dose observed in earlier studies.
  • Urinary recovery of tobramycin was measured by determining the cumulative amount of tobramycin recovered in urine collected for 24 hours after dosing.
  • measurable tobramycin i.e., above the lower limit of quantifiability [LOQ] of the assay
  • LOQ lower limit of quantifiability
  • Substantial variability is known to occur among patients in the rate and extent of uptake, renal accumulation, and elimination of aminoglycoside antibiotics, even in patients with normal renal function. Each of these factors may lengthen the amount of time that measurable concentrations of aminoglycoside antibiotics may be detected in serum and urine.
  • the present study employed a prestudy washout interval of 7 days from previous prescription aminoglycoside antibiotic use and a 7-day interval between the 3 single doses of TOBI, an aminoglycoside antibiotic, during the crossover treatment periods. It is plausible that prestudy and on-study washout intervals in the study may have been too short for complete elimination of residual tobramycin previously administered, if any. Measurable amounts of tobramycin for these patients would have had little effect on study results, since the amounts and concentrations detected were very small in nearly all cases, and no unusually high serum or urine tobramycin results were noted during the study.
  • Aerodose inhaler was a safe and efficient aerosolization and delivery device for TOBI during the study.
  • the study of this example was designed as an open label, randomized, single center, single dose, two period crossover Phase I study of aerosol delivery characteristics and safety of two inhalation devices in healthy adult volunteers.
  • a maximum of 14 healthy male or non-pregnant, non breast-feeding female volunteers aged 18 to 65 years of age were to receive in random order two single doses of aerosolized antibiotic mixed with a sterile radiotracer (technetium bound to diethylenetriaminepentaacetic acid: 99m Tc DTPA) separated by a washout interval of a minimum of 44 hours between doses.
  • a sterile radiotracer technetium bound to diethylenetriaminepentaacetic acid: 99m Tc DTPA
  • Radiolabeled aerosols consisted of a single 300 mg dose in a 5 mL solution of TOBI delivered by the control delivery system (PARI LC PLUS jet nebulizer with a PulmoAide compressor) and a single 60 mg dose in a 1 mL solution of TOBI delivered by the experimental delivery system (Aerodose inhaler).
  • Aerosol delivery characteristics of control and experimental delivery systems were compared on the basis of lung deposition of radiolabeled tobramycin determined by gamma scintigraphy, time to complete nebulization of aerosolized doses, serum concentrations of tobrarnycin determined by Abbott TDxFLx assays, and serum tobramycin pharmacokinetic parameters.
  • the duration of study participation for each subject was to be approximately five weeks including a screening period of up to 3 weeks in duration, two treatment periods of approximately 9 hours each separated by a minimum 44-hour washout interval, and a follow-up period through 2 weeks after the end of dosing.
  • TOBI® was administered by inhalation as a single 300 mg dose and as a single 60 mg dose to each subject during the study.
  • the 300 mg dose was supplied as a commercial ampoule of TOBI.
  • the 60 mg dose of tobramycin solution was prepared by study site personnel by withdrawing 1.0 mL of solution from the 300 mg/5 mL commercial ampoule of TOBI into two unit dose syringes containing 0.5 mL each.
  • each subject was to self-administer two single aerosolized doses of radiolabeled ( 99m Tc DTPA) TOBI, one dose in each of two crossover treatment periods, according to the randomization scheme for the study. Subjects were instructed to use nose clips and breathe in a normal breathing pattern while inhaling the medication according to the instructions for use for each inhaler.
  • radiolabeled 99m Tc DTPA
  • Control Treatment Delivery System PARI LC PLUS jet nebulizer with DeVilbiss PulmoAide compressor delivering 300 mg (5 mL) of TOBI.
  • Aerodose inhaler When the Aerodose inhaler was used, one 0.5 mL aliquot of radiolabeled TOBI was added to the drug reservoir and nebulized to dryness. A second 0.5 mL dose was then added to the reservoir and nebulized to dryness. The inhaler was surrounded with an exhaled air collection box. Air was drawn through a filter at the back of the box using a vacuum pump.
  • Enrolled volunteers were randomly assigned to two treatment sequence groups as illustrated below according to a randomization scheme.
  • period 1 Aerodose with TOBI 60 mg
  • period 2 PARI LC PLUS with TOBI 300 mg
  • TOBI formulations were radiolabeled with 99m Tc-DTPA in preparation for gamma scintigraphy to determine posttreatment tobramycin deposition in the lungs.
  • Subjects practiced the inhalation procedure with both control and experimental devices filled with normal saline.
  • the inhaler was filled with the radiolabeled formulation, and the subject inhaled the radiolabeled dose until the nebulizer was dry and nebulization was stopped.
  • anterior and posterior abdominal views if necessary, i.e., if activity had spread through the intestine, beyond the field of view in either of the chest images;
  • a posterior lung ventilation scan was performed using the radioactive inert gas, krypton ( 81m Kr), to determine the lung outlines.
  • the lung outlines were used to divide lung images of each subject into central, intermediate, and peripheral lung zones in order to determine the amount of aerosolized tobramycin deposited in each of these zones 17 .
  • Lung ventilation scans taken for subjects who participated in earlier studies were acceptable for use for this study provided the scan was obtained within the last five years and the subject had no record of serious lung disease in the intervening period.
  • peripheral lung zone deposition (% of metered dose);
  • oropharyngeal deposition including esophagus and stomach (% of metered dose);
  • inhaler deposition PARI LC PLUS or AeroDose (% of metered dose);
  • radioaerosol in exhaled air (filters) (% of metered dose);
  • radioaerosol on Aerodose exhaled air collection box and subject tissues (% of metered dose).
  • the counts in each area were expressed as a percentage of the metered dose that was determined from the sum of the total body counts in addition to those deposited on the inhaler and the exhalation filter. Since the volume of TOBI placed into each of the two inhalers was different, direct comparisons of the percentage deposition values was problematic. To aid interpretation of the data, the percentage deposition values were multiplied by the nominal metered dose (300 mg for the PARI LC PLUS and 60 mg for the Aerodose inhaler) to obtain amounts of drug deposited in milligrams for each of the deposition parameters listed above.
  • nebulization time was another objective of the study. Elapsed time from the start of nebulization (defined as the subject's first tidal breath after the inhaler was in place) until no more TOBI solution was aerosolized by the inhaler was measured by staff at the site using a stopwatch. Nebulization time was not to include time needed for instillation of drug into the nebulizer between the repeat filling of the Aerodose inhaler. The length of any interruption in nebulization and the reason for interruption were recorded.
  • Serum tobramycin concentrations were determined for the present study, and pharmacokinetic parameters were calculated, to provide preliminary estimates of the bioavailability of 60 mg TOBI delivered by the Aerodose system in comparison with that of the marketed 300 mg TOBI formulation. Additionally, unusually high serum tobramycin results ( ⁇ 4 ⁇ g/mL) were considered an important measure of safety during the study.
  • Venous blood samples (8 mL) for the determination of serum tobramycin concentrations were collected by intravenous cannula or by venipuncture before each single dose of TOBI and at 30 minutes and 1, 2, 4, and 8 hours after completion of dosing. The first one mL of blood withdrawn from the cannula was discarded, and the subsequent 7 mL was withdrawn into serum sampling tubes. Cannulae were frequently flushed with saline during the course of the treatment day.
  • the maximum tobramycin concentration (C max ) and the time to reach C max (T max ) were the observed values.
  • the elimination rate constant (k el : used to calculate AUC 0- ⁇ ; see next paragraph) was calculated as the negative slope of the log plasma concentration vs. time plot using the last two measurable concentrations. Use of more than two concentrations at or after T max is preferred for calculation of the elimination rate constant; however, several subjects had only two measurable tobramycin concentrations at the terminal phase after TOBI 60 mg using the Aerodose inhaler.
  • the alternate method of calculating k el using the last two measurable concentrations was employed for all subjects for both period 1 and period 2.
  • AUC 0-8 Area under the curve through 8 hours postdose (AUC 0-8 ) and extrapolated to infinity (AUC 0- ⁇ ) were calculated for serum tobramycin concentrations using the linear trapezoid rule. Actual nebulization time was added to the time between predose and 30 minutes after the end of inhalation when calculating AUC 0-8 . AUC 0- ⁇ was extrapolated from the last measurable concentration to infinite time by adding the quantity equal to the last measurable concentration divided by the elimination rate constant (k el ).
  • Serum pharmacokinetic parameters (C max , AUC 0-8 , and AUC 0- ⁇ ) were analyzed for differences between delivery systems using a repeated measures analysis of variance.
  • the statistical model included study period and delivery systems as fixed effects and subject as the random effect.
  • the carryover effect from treatment period 1 to 2 was also investigated.
  • nebulization time i.e., time required from first tidal breath until the nebulizer ran dry
  • TABLE 14 MEAN (SD) NEBULIZATION TIME Intent to Treat (n 10) Nebulization Time* TOBI 300 mg TOBI 60 mg Parameter PARI LC PLUS AeroDose p-value Nebulization Time (minutes): Mean 20.40 5.70 0.005 SD 3.47 1.16 Minimum 17.0 4.0 Maximum 29.0 8.0 no. subjects 10 10
  • FIGS. 1 through 20 graphically illustrate serum tobramycin concentrations before and after period 1 and period 2 dosing for all individual subjects.
  • T 1/2 The mean elimination half-life was 4.269 hours for the PARI LC PLUS system and 6.071 hours for the Aerodose system (Table 7).
  • the mean whole lung deposition using the PARI LC PLUS nebulizer was 8.2% (24.5 mg) of the 300 mg TOBI dose.
  • the mean whole lung deposition using the Aerodose inhaler was 34.8% (20.9 mg) of the 60 mg TOBI dose.
  • a mean of 14.4% (43.3 mg) and 31.5% (18.9 mg) of the corresponding doses were deposited in the oropharynx using the PARI LC PLUS and Aerodose inhalers, respectively. Both inhaler systems were configured such that each subject's exhaled material was collected and did not escape with radioactive aerosol into the surrounding atmosphere.
  • the PARI LC PLUS nebulizer also included a system to collect any radiolabeled droplets escaping from the nebulizer.
  • AeroDoseTM inhaler was more efficient in delivery of aerosolized tobramycin to the lungs of healthy adult volunteers than the approved PARI LC PLUS jet nebulizer with DeVilbiss PulmoAide compressor. Since the Aerodose inhaler is breath-actuated and generates aerosol only during inhalation, proportionally more of the Aerodose dose should be delivered to the lungs than is delivered by the PARI LC PLUS, and there should be minimal wastage of drug by aerosolization during exhalation or by incomplete aerosolization of the contents of the drug reservoir.
  • both the Aerodose inhalers and PARI LC PLUS nebulizers wasted drug product in the present study by reason of retention of radiolabeled drug on or in the inhaler or deposition of drug on the exhalation filter (an average of approximately 19 of 60 mg wasted when the Aerodose inhaler was used and approximately 223 of 300 mg wasted when the PARI LC PLUS nebulizer was used).
  • the proportion of the total dose wasted using the Aerodose inhaler was less than half of that wasted using the approved PARI LC PLUS nebulizer.
  • the Aerodose inhaler also appeared to exhibit better “targeting” or delivery of the dose to the lungs, the target site of the usual P. aeruginosa infection in cystic fibrosis patients, than the PARI LC PLUS nebulizer.
  • the Aerodose inhaler deposited slightly more tobramycin in the lungs than in the oropharynx, esophagus, and stomach (lungs 34.8% vs. 31.5% of the 60 mg dose).
  • the PARI LC PLUS nebulizer deposited proportionally less of the dose in the lungs than in oropharynx, esophagus, and stomach (lungs 8.2% vs. 14.4% of the 300 mg dose).
  • the ratio of lung to oropharyngeal, esophagus, and stomach combined was approximately 1.1 for the Aerodose inhaler and 0.6 for the PARI LC PLUS nebulizer.
  • Aerodose inhaler In addition to greater efficiency by greater delivery of drug to the lungs and proportionally greater targeting of the lungs, the Aerodose inhaler was also anticipated to be more efficient by reason of proportionally greater delivery of tobramycin to peripheral rather than central lung regions.
  • the Aerodose inhaler deposited 13.2% (7.9 mg) of the 60 mg dose in the peripheral airways, while the PARI LC PLUS nebulizer deposited 3.1% (9.3 mg) in peripheral airways.
  • Results of the study also showed that the Aerodose inhaler required significantly less nebulization time than the PARI LC PLUS nebulizer (mean 20.4 vs. 5.7 minutes, respectively).
  • the 5.7 minute average nebulization time for the Aerodose inhaler did not include the amount of time needed to fill the drug reservoir before nebulization of the second aliquot. Based on nebulization time results and other inhaler features including portability, ease of use, and lack of a need for a compressor, it is anticipated that the Aerodose inhaler would improve patient compliance.
  • Results of the study also showed that single doses of TOBI 300 mg delivered using the PARI LC PLUS jet nebulizer and of TOBI 60 mg delivered using the Aerodose breath actuated nebulizer were safe and well-tolerated by healthy adult male and female volunteers. No instances of bronchospasm were observed, and no notable quantitative changes in pulmonary function were seen. No notable adverse events (AEs) were reported by subjects, and there were no apparent differences between treatment groups in incidence of any AE. Six treatment emergent AEs were reported by 4 subjects, but all events were mild in intensity. Two instances of headache were considered possibly or definitely related to treatment. No clinically significant laboratory results or changes in results were observed. No adverse vital signs, body weights, physical findings, or electrocardiogram results were observed. No evidence of systemic toxicity, as measured by unusually high serum tobramycin concentrations, was observed.
  • the study was designed as an open label, randomized, single-dose, multicenter, two treatment, active-control, and parallel trial. Each patient was administered a single aerosolized dose of study drug with either the control delivery system or the experimental delivery system. In accordance with the study design, a total of 36 eligible male and female patients 12 years of age or older with a confirmed diagnosis of cystic fibrosis were enrolled with a minimum of 4 patients at each site. A 2:1 randomization ratio was employed for assignment of patients to the treatment groups. In the presence of the investigator or study coordinator, each patient was to self-administer either a single dose of 300 mg TOBI® with the control delivery treatment or a single dose of 420 mg Tobramycin Solution for Inhalation with the experimental delivery treatment as listed below.
  • Aerosolized 300 mg TOBI® was delivered by PARI LC PLUS jet nebulizer/DeVilbiss PulmoAide compressor: Preservative free tobramycin for inhalation 60 mg/mL (excipient 5 mL of 1/4 normal saline adjusted to a pH of 6.0 ⁇ 0.5); 300 mg in 5 mL; lot number 03K1C (TOBI® at 60 mg/mL).
  • Aerosolized 420 mg Tobramycin Solution for Inhalation was delivered by PARJ LC PLUS jet nebulizer/Invacare MOBILAIRE compressor: Preservative free tobramycin 120 mg/mL (excipient 3.5 mL of 1 ⁇ 4 normal saline adjusted to a pH of 6.0 ⁇ 0.5); 420 mg in 3.5 mL.
  • Both 300 mg TOBI® and 420 mg Tobramycin Solution for Inhalation are sterile, non-pyrogenic, preservative-free antibiotics prepared for aerosolization.
  • Each mL of TOBI® contains 60 mg tobramycin and 2.25 mg sodium chloride in sterile water for injection, pH 6.0 ⁇ 0.5 (control treatment).
  • Each mL of TSI contains 120 mg tobramycin and 2.25 mg sodium chloride in sterile water for injection, pH 6.0+0.5 (experimental treatment).
  • Drug supplies for this study were manufactured by Automated Liquid Packaging (ALP), Woodstock, Ill. All repackaging, labeling, and distribution for clinical use was provided by Packaging Coordinators, Inc. (PCI), Philadelphia, Pa. Study drug and device supplies were shipped from Chiron Corporation, Emeryville, Calif. for each patient upon enrollment in the study.
  • the duration of study participation for each patient was approximately two weeks including a brief (one day one week before treatment) screening period, one day treatment period, and a follow-up one-week after treatment. Study treatments were evaluated for safety and aerosol delivery characteristics up to eight hours post-dose on the day of the single dose treatment administration. The patient was to return to the clinic for a seven day post-treatment follow-up assessment of safety. There were no planned interim safety analyses.
  • Rate of bronchospasm measured by the percent of patients with >10% and >20% relative decrease in FEV 1 % from pre-dose to 30 minutes post-dose was summarized and compared between treatments using the Fisher's exact test.
  • Aerosol delivery variables were tobramycin concentrations in sputum and serum, sputum and serum tobramycin pharmacokinetic parameters, and aerosol nebulization time.
  • Safety variables were the incidence and severity of bronchospasm, measured as the number of patients experiencing a >10% and a >20% decrease in forced expiratory volume in one second (FEV 1 ) within 30 minutes after dosing (a ⁇ 20% decrease in FEV 1 was considered clinically significant), the incidence of treatment emergent adverse events (AEs), clinical laboratory test results, the number of patients with serum tobramycin concentrations ⁇ 4 ⁇ g/mL, physical examination findings, and vital signs results.
  • FEV 1 forced expiratory volume in one second
  • AEs treatment emergent adverse events
  • Sputum Tobramycin Concentrations Sputum samples were expectorated by patients from a deep cough and collected before day 1 dosing (predose) and at 0.25, 1, 2, 4, and 8 h after the end of the nebulization period. Sputum samples were collected as close as possible to specified times and were considered to have been drawn on time within ⁇ 2 minutes for the 15-minute posttreatment collection and within ⁇ 10 minutes for the 1-, 2-, 4-, and 8-hour posttreatment collections. Samples collected outside these intervals were considered protocol deviations. A minimum 100 mg sputum (not saliva) sample was collected before the single dose of study treatment to determine the baseline tobramycin concentration.
  • Sputum standard samples were prepared by spiking diluted pooled sputum from CF patients with tobramycin to final concentrations of 0, 20, 40, 100, 200, 400, and 1000 ⁇ g/g of sputum.
  • Assay quality control samples were prepared by spiking diluted pooled sputum to contain 40, 300, and 800 ⁇ g/g.
  • the internal standard sisomycin 100 ⁇ L, 0.15 mg/mL in Tris buffer was added to 100 ⁇ L of each standard, control, and subject sample, followed by 400 ⁇ L of acetonitrile and 50 ⁇ L of 2,4-dinitrofluorobenzene (0.17 g/mL).
  • the mobile phase consisted of 0.2% acetic acid in acetonitrile (39/61, v/v), pumped at a rate of 1.5 mL/min for 5 min, 2.0 mL/min for an additional 9 or 10 min, depending on the length of the run.
  • Waters Millennium-32 C/S LC Software version 3.20 was used to operate the Waters HPLC instruments as well as acquire raw data, process, compute, and report the analytical results.
  • the ratio of the peak height of tobramycin to the internal standard sisomycin (PHR) was calculated.
  • the assay was completed in 8 runs. Retention time ranges of 4.2 to 4.4 min, and 10.8 to 11.8 min were observed for tobramycin and sisomycin, respectively.
  • Serum Tobramycin Concentrations Blood samples were collected at predose and at 0.167, 1, 2, 4, 6, and 8 h after the end of the nebulization period. Samples were collected as close as possible to specified times and were considered to have been drawn on time within ⁇ 2 minutes for the 10-minute posttreatment collection and within ⁇ 10 minutes for the 1-, 2-, 4-, 6-, and 8-hour posttreatment collections. Samples collected outside these intervals were considered protocol deviations. Serum was harvested and stored at ⁇ 70° C. or below until analysis. Concentrations of tobramycin in serum were analyzed with a modified fluorescence polarization immunoassay (FPIA) method using the Abbott TDx®/TDxFLx® System.
  • FPIA fluorescence polarization immunoassay
  • the lower limit of quantitation was 0.050 ⁇ g/mL.
  • the precision of the assay, as reflected by the CV of the quality control samples, was 3.3%, 4.9%, and 4.9% for the 0.150, 0.400, and 0.750 ⁇ g/mL samples, respectively.
  • the accuracy of the method, reflected by the mean interassay recoveries of the quality control samples, was 101%, 103%, and 104% for the 0.150, 0.400, and 0.750 ⁇ g/mL samples, respectively. Overall, this method exhibited suitable accuracy and precision for pharmacokinetic analysis.
  • Nebulization time was defined as the length of time from the start of the patient's first tidal breath to completion of aerosol administration. Aerosol administration was complete when the nebulizer began to sputter. If aerosol administration was interrupted for any reason, the time of interruption and start and stop times of continued aerosol administration were recorded. If dosing was interrupted, nebulization time was considered to be not calculable.
  • Residual Tobramycin in the Nebulizer The amount of residual tobramycin solution remaining in the nebulizer after completion of aerosol administration was determined by recording pretreatment and posttreatment weight of the nebulizer system including nebulizer, filter valve, and study drug.
  • the research coordinator collected residual study drug remaining in the nebulizer after aerosol administration into a vial labeled with patient information. The vial was returned for measurement of the amount of drug output from the nebulizer and for determination of the extent of the concentration of study drug left in the nebulizer.
  • Bronchospasm The study protocol prospectively identified bronchospasm as an adverse airway response to inhalation of aerosolized antibiotic of particular relevance to patients with cystic fibrosis.
  • patients performed spirometry (pulmonary function) tests to measure FEV 1 before and 30 minutes following completion of study treatment administration according to the method described in the protocol.
  • Airway response to the study drug was assessed by evaluating the relative percent change in FEV 1 from predose to 30 minutes after the end of treatment using the following formula.
  • Bronchospasm was defined as a decrease in FEV 1 of ⁇ 10% at 30 minutes after dosing, relative to the predose result. A decrease in FEV 1 of ⁇ 20% was considered to represent clinically significant bronchospasm. Moreover, if there was a posttreatment decrease in FEV 1 of ⁇ 30%, spirometry was to be repeated until the FEV 1 decrease was ⁇ 10% below the predose result. An FEV 1 % decrease ⁇ 30%, and all symptoms associated with the change in pulmonary function, were to be recorded as adverse events. The protocol defined the severity of decrease in FEV 1 based in part on the National Cancer Institute (NCI) Common Toxicity Criteria Adverse Events Grading Scale.
  • NCI National Cancer Institute
  • Serum assay results were screened for tobramycin concentrations >4 ⁇ g/mL from specimens collected from 10 minutes through 8 hours after completion of study treatments. In parallel, patient records and CRFs were examined for evidence of systemic toxicity potentially related to elevated tobramycin levels. Assay results were not available until after patients' discharge from the study, so screening for unusually high serum tobramycin concentrations and evidence of systemic toxicity was undertaken when all pertinent results were received.
  • V z /F CL po / ⁇ z
  • t 1/2 is the terminal half-life
  • CL/F is the total body clearance
  • Vz/F is the terminal volume of distribution.
  • Case report form data were entered in duplicate into a ClintrialTM database by the department of Biostatistics and Clinical Data Management (BCDM) at Chiron Corporation. Data quality assurance was performed using PL/SQL and SASTM 6.12 or higher software (SAS Institute, Cary, N.C.). Analysis was performed by Chiron Corporation, using SAS version 6.12 or higher software, based on a predefined analysis plan developed by Chiron Corporation. The estimated overall database error rate was 0.xx % with an upper 95% confidence limit of 0.xx %. This upper confidence limit is below the departmental standard of 0.5%.
  • Aerosol delivery was characterized on the basis of serum and sputum tobramycin concentrations, derived serum and sputum pharmacokinetic parameters, and nebulization time.
  • the effect of treatment 300 mg TOBI vs 420 mg TSI), gender, and age group (less than 18, 18 years or older) on the AUC, C max , ⁇ z , CL/F, and Vz/F of tobramycin in serum, and on the AUC, C max , and ⁇ z of tobramycin in sputum, was analyzed by a three-way analysis of variance.
  • SD( ⁇ overscore ( ⁇ z ) ⁇ ) is the standard error of the mean terminal rate constant at each dose.
  • the primary safety variable was the rate of bronchospasm, defined as a ⁇ 10% decrease in FEV 1 from predose to 30 minutes after treatment on day 1 of the study.
  • Secondary safety variables were (a) the rate of clinically significant bronchospasm, defined as a ⁇ 20% decrease in FEV 1 from predose to 30 minutes after treatment on day 1, and (b) the relative change in FEV 1 from predose to 30 minutes after treatment on day 1.
  • the rates of occurrence of all instances of bronchospasm (FEV 1 % decrease ⁇ 10%) and of all instances of clinically significant bronchospasm (FEV 1 % decrease ⁇ 20%) were analyzed to assess the statistical significance of test vs. reference treatment differences using the Fisher's Exact test.
  • Adverse Events The total incidence of individual treatment emergent adverse events (percent of patients who experienced the event at least once during or after study treatment) was evaluated descriptively for any noteworthy differences between test and reference treatments. AEs were also summarized by severity (mild, moderate, severe) and drug relationship (unrelated, possibly related) for test and reference treatments.
  • Serum and sputum pharmacokinetic parameters are summarized in Tables 19 and 20 as follows.
  • TABLE 19 SERUM PHARMACOKINETIC PARAMETERS (MEAN ⁇ SD) OF TOBRAMYCIN AFTER ADMINISTRATION OF 300 MG TOBI AND 420 MG TSI Parameter 300 mg TOBI 420 mg TSI AUC ( ⁇ g h/mL) 4.38 ⁇ 1.97 4.41 ⁇ 1.69 C max ( ⁇ g/mL) 0.861 ⁇ 0.344 0.906 ⁇ 0.542 Median t max (h) 1 (1-4)* 1 (0.17-2) ⁇ z (h ⁇ 1 ) 0.250 ⁇ 0.052 0.243 ⁇ 0.098 t 1 ⁇ 2 (h) 2.78 ⁇ 0.58 2.86 ⁇ 1.15 CL/F (L/h) 88 ⁇ 62 114 ⁇ 59 V Z /F (L) 379 ⁇ 325 511 ⁇ 278
  • Nebulization time was substantially reduced during administration of the test 420 mg TSI formulation below that observed during administration of the marketed 300 mg TOBI® formulation.
  • Mean ⁇ SD total nebulization time was 9.7 ⁇ 3.0 minutes during 420 mg TSI administration compared to 18.1 ⁇ 3.6 minutes during 300 mg TOBI® administration (Table 21).
  • Nebulizer Weight Nebulizer weight changes from before to after dosing indicated that the test 420 mg TSI formulation delivered less product to patients than the marketed 300 mg TOBI® formulation. Mean ⁇ SD amounts of product delivered to patients was 1.86 ⁇ 0.53 gm during 420 mg TSI administration and 2.74 ⁇ 1.64 gm during 300 mg TOBI® administration (Table 14.2.2.2), as summarized in Table 11.4-4 below. These findings likely reflect the smaller 3.5 mL volume of TSI formulation in the nebulizer compared to the 5 mL volume of the TOBI® formulation.
  • Aerosol delivery findings indicate that it is possible to achieve comparable serum and sputum levels of tobramycin to the 300 mg TOBI® formulation by using the 420 mg TSI formulation.
  • Present findings also indicate that the reduced nebulization times and reduced amount of product delivered to patients during administration of the 420 mg TSI treatment did not change the pharmacokinetics of tobramycin relative to the marketed 300 mg TOBI® formulation.
  • TSI Tobramycin Solution for Inhalation
  • Aerosol delivery findings indicate that it is possible to achieve comparable serum and sputum levels of tobramycin to the 300 mg TOBI® formulation by using the 420 mg TSI formulation. Current findings also indicate that the reduced nebulization times during administration of the 420 mg TSI treatment did not change the pharmacokinetics of tobramycin relative to the marketed 300 mg TOBI®formulation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
US10/151,701 2001-05-18 2002-05-17 Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics Abandoned US20030143162A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US10/151,701 US20030143162A1 (en) 2001-05-18 2002-05-17 Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
US10/743,529 US6890907B2 (en) 2001-05-18 2003-12-22 Methods and unit dose formulations for the inhalation administration of tobramycin
US10/883,143 US20040265241A1 (en) 2001-05-18 2004-07-01 Methods for the inhalation administration of antibiotics
US11/125,670 US20050207987A1 (en) 2001-05-18 2005-05-10 Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
US11/126,108 US20050201947A1 (en) 2001-05-18 2005-05-10 Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
US11/923,486 US7825095B2 (en) 2001-05-18 2007-10-24 Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
US12/884,505 US20110005518A1 (en) 2001-05-18 2010-09-17 Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
US13/295,228 US8507454B2 (en) 2001-05-18 2011-11-14 Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29223401P 2001-05-18 2001-05-18
US10/151,701 US20030143162A1 (en) 2001-05-18 2002-05-17 Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/743,529 Continuation US6890907B2 (en) 2001-05-18 2003-12-22 Methods and unit dose formulations for the inhalation administration of tobramycin

Publications (1)

Publication Number Publication Date
US20030143162A1 true US20030143162A1 (en) 2003-07-31

Family

ID=23123791

Family Applications (8)

Application Number Title Priority Date Filing Date
US10/151,701 Abandoned US20030143162A1 (en) 2001-05-18 2002-05-17 Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
US10/743,529 Expired - Lifetime US6890907B2 (en) 2001-05-18 2003-12-22 Methods and unit dose formulations for the inhalation administration of tobramycin
US10/883,143 Abandoned US20040265241A1 (en) 2001-05-18 2004-07-01 Methods for the inhalation administration of antibiotics
US11/125,670 Abandoned US20050207987A1 (en) 2001-05-18 2005-05-10 Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
US11/126,108 Abandoned US20050201947A1 (en) 2001-05-18 2005-05-10 Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
US11/923,486 Expired - Lifetime US7825095B2 (en) 2001-05-18 2007-10-24 Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
US12/884,505 Abandoned US20110005518A1 (en) 2001-05-18 2010-09-17 Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
US13/295,228 Expired - Fee Related US8507454B2 (en) 2001-05-18 2011-11-14 Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics

Family Applications After (7)

Application Number Title Priority Date Filing Date
US10/743,529 Expired - Lifetime US6890907B2 (en) 2001-05-18 2003-12-22 Methods and unit dose formulations for the inhalation administration of tobramycin
US10/883,143 Abandoned US20040265241A1 (en) 2001-05-18 2004-07-01 Methods for the inhalation administration of antibiotics
US11/125,670 Abandoned US20050207987A1 (en) 2001-05-18 2005-05-10 Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
US11/126,108 Abandoned US20050201947A1 (en) 2001-05-18 2005-05-10 Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
US11/923,486 Expired - Lifetime US7825095B2 (en) 2001-05-18 2007-10-24 Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
US12/884,505 Abandoned US20110005518A1 (en) 2001-05-18 2010-09-17 Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
US13/295,228 Expired - Fee Related US8507454B2 (en) 2001-05-18 2011-11-14 Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics

Country Status (11)

Country Link
US (8) US20030143162A1 (enrdf_load_stackoverflow)
EP (2) EP2186508A3 (enrdf_load_stackoverflow)
JP (2) JP2004534763A (enrdf_load_stackoverflow)
AT (1) ATE322249T1 (enrdf_load_stackoverflow)
AU (1) AU2010210026A1 (enrdf_load_stackoverflow)
CA (1) CA2447600C (enrdf_load_stackoverflow)
DE (1) DE60210402T2 (enrdf_load_stackoverflow)
DK (1) DK1320355T3 (enrdf_load_stackoverflow)
ES (1) ES2261735T3 (enrdf_load_stackoverflow)
PT (1) PT1320355E (enrdf_load_stackoverflow)
WO (1) WO2002094217A1 (enrdf_load_stackoverflow)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080063606A1 (en) * 2001-12-19 2008-03-13 Tarara Thomas E Pulmonary delivery of aminoglycoside
US20110195920A1 (en) * 2008-10-24 2011-08-11 Cempra Pharmaceuticals, Inc. Biodefenses using triazole-containing macrolides
US8664187B2 (en) 2004-06-18 2014-03-04 Novartis Ag Methods of treatment of endobronchial infections
WO2014152326A1 (en) * 2013-03-14 2014-09-25 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
US9051346B2 (en) 2010-05-20 2015-06-09 Cempra Pharmaceuticals, Inc. Process for preparing triazole-containing ketolide antibiotics
US9200026B2 (en) 2003-03-10 2015-12-01 Merck Sharp & Dohme Corp. Antibacterial agents
RU2597842C2 (ru) * 2010-07-12 2016-09-20 Кселлия Фармасьютикалз Апс Лечение легочных инфекций с помощью введения тобрамицина путем аэролизации
US9453042B2 (en) 2007-10-25 2016-09-27 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
US9480679B2 (en) 2009-09-10 2016-11-01 Cempra Pharmaceuticals, Inc. Methods for treating malaria, tuberculosis and MAC diseases
US9751908B2 (en) 2013-03-15 2017-09-05 Cempra Pharmaceuticals, Inc. Convergent processes for preparing macrolide antibacterial agents
US9815863B2 (en) 2010-09-10 2017-11-14 Cempra Pharmaceuticals, Inc. Hydrogen bond forming fluoro ketolides for treating diseases
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
US9999604B2 (en) 2016-11-17 2018-06-19 Cmpd Licensing, Llc Compounded solutions of diclofenac and lidocaine and methods
US10188674B2 (en) 2012-03-27 2019-01-29 Cempra Pharmaceuticals, Inc. Parenteral formulations for administering macrolide antibiotics
US10525025B2 (en) 2016-11-17 2020-01-07 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
US10532080B2 (en) 2014-10-03 2020-01-14 Xellia Pharmaceuticals Aps Sulfomethylated polymixin compositions
US10617703B2 (en) 2014-12-10 2020-04-14 Cmpd Licensing, Llc Compositions and methods for treating an infection
US10640536B2 (en) 2013-01-11 2020-05-05 Xellia Pharmaceuticals Aps Polymyxins, compositions, methods of making and methods of use
US10711040B2 (en) 2014-07-09 2020-07-14 Xellia Pharmaceuticals Aps Low substituted polymyxins and compositions thereof
US10898491B2 (en) 2015-12-18 2021-01-26 Cmpd Licensing, Llc Compositions and methods for treating an infection
US10898455B2 (en) 2016-01-07 2021-01-26 Cmpd Licensing, Llc Urea cream formulations
US11033602B2 (en) 2014-10-03 2021-06-15 Xellia Pharmaceuticals Aps Inhalation device
US11278590B2 (en) 2015-08-05 2022-03-22 Cmpd Licensing, Llc Compositions and methods for treating nail infections
US11684567B2 (en) 2015-08-05 2023-06-27 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11690815B2 (en) 2015-08-05 2023-07-04 Cmpd Licensing Llc Hyperkeratotic skin condition treatments and compositions
US11793783B2 (en) 2015-08-05 2023-10-24 Cmpd Licensing, Llc Compositions and methods for treating an infection
US12029812B2 (en) 2015-08-05 2024-07-09 Cmpd Licensing, Llc Compositions and methods for treating an infection

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW465235B (en) 1998-09-17 2001-11-21 United Video Properties Inc Electronic program guide with digital storage
CA2447600C (en) * 2001-05-18 2015-10-20 Chiron Corporation Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
US20040022740A1 (en) * 2001-07-10 2004-02-05 Baker William R. Macrolide formulations for inhalation and methods of treatment of endobronchial infections
EP1424889A4 (en) * 2001-08-20 2008-04-02 Transave Inc PROCESS FOR TREATING LUNG CANCERS
US8245708B2 (en) * 2002-05-07 2012-08-21 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
US7607436B2 (en) * 2002-05-06 2009-10-27 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
CN1681478A (zh) * 2002-08-02 2005-10-12 川塞夫有限公司 铂聚集体及其制备方法
US9186322B2 (en) * 2002-08-02 2015-11-17 Insmed Incorporated Platinum aggregates and process for producing the same
AU2002953095A0 (en) * 2002-11-29 2002-12-19 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
AU2004281532B2 (en) * 2003-10-15 2010-03-18 Pari Pharma Gmbh Liquid preparation containing tobramycin
US20050249822A1 (en) * 2004-03-18 2005-11-10 Transave, Inc. Administration of cisplatin by inhalation
US20070065522A1 (en) * 2004-03-18 2007-03-22 Transave, Inc. Administration of high potency platinum compound formulations by inhalation
EP2266534B1 (en) * 2004-05-17 2012-09-26 Gilead Sciences, Inc. Aerosolized Fosfomycin/Tobramycin combination for the treatment of Cystic Fibrosis
EP1755623A4 (en) * 2004-05-21 2007-10-17 Transave Inc TREATMENT OF LUNG DISEASES AND BEFORE A PULMONARY DISEASE
WO2006055352A2 (en) * 2004-11-08 2006-05-26 Transave, Inc. Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally
AU2013206401B2 (en) * 2005-09-29 2016-06-23 Novartis Ag Antibiotic formulations, unit doses, kits, and methods
JP2009510077A (ja) 2005-09-29 2009-03-12 ネクター セラピューティックス 抗生物質製剤、単位用量、キットおよび方法
US20070190182A1 (en) * 2005-11-08 2007-08-16 Pilkiewicz Frank G Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
WO2007056236A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with lipid-based platinum compound formulations administered intravenously
WO2007056263A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
WO2007064658A2 (en) * 2005-11-30 2007-06-07 Transave, Inc. Safe and effective methods of administering therapeutic agents
JP5324223B2 (ja) 2005-12-08 2013-10-23 トランセイブ， インク． 肺感染症を治療する抗感染薬の脂質ベースの組成物及びその使用法
WO2007070875A1 (en) * 2005-12-15 2007-06-21 Aerosol Science Laboratories, Inc. Treatment of active infections and related compositions
JP2008199905A (ja) * 2007-02-16 2008-09-04 Snow Brand Milk Prod Co Ltd 乳酸菌生残性向上剤
JP2011517082A (ja) * 2008-04-02 2011-05-26 エヌエックスピー ビー ヴィ 半導体デバイスの製造方法および半導体デバイス
DK2550286T3 (en) 2010-03-22 2016-02-29 Cempra Pharmaceuticals Inc CRYSTALLINE FORMS OF A MACROLID AND APPLICATIONS THEREOF
CA2841272C (en) 2011-07-12 2019-01-15 Alan Bruce Montgomery Formulations of amikacin and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (vap) and ventilator associated tracheal (vat) bronchitis
US8826904B2 (en) 2011-07-12 2014-09-09 Cardeas Pharma Corporation Formulations of aminoglycoside and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis
GB201208080D0 (en) 2012-05-09 2012-06-20 Norton Healthcare Ltd Tobramycin formulation
EP2892524B1 (en) 2012-09-04 2020-11-25 Eleison Pharmaceuticals, LLC Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin
ES2743039T3 (es) 2012-11-29 2020-02-18 Insmed Inc Formulaciones de vancomicina estabilizada
SI3142643T1 (sl) 2014-05-15 2019-11-29 Insmed Inc Postopki za zdravljenje pljučnih netuberkuloznih mikobakterijskih infekcij
US11571386B2 (en) 2018-03-30 2023-02-07 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
WO2020163416A1 (en) * 2019-02-05 2020-08-13 Mylan Inc Devices and methods for tobramycin inhalation treatment

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993223A (en) 1974-07-25 1976-11-23 American Home Products Corporation Dispensing container
US4502616A (en) 1982-01-04 1985-03-05 Health Care Concepts, Inc. Single use vial
GB8801655D0 (en) 1988-01-26 1988-02-24 Waverley Pharma Ltd Ampoules
DE68904082T2 (de) 1988-01-28 1993-07-29 Lameplast Srl Flaeschchenkette fuer pharmazeutische, kosmetische und andere produkte.
GB8802349D0 (en) 1988-02-03 1988-03-02 Waverley Pharma Ltd Ampoule with luer
DE3916840A1 (de) 1988-09-21 1990-03-29 Bernd Hansen Ampulle
US5409125A (en) 1989-12-11 1995-04-25 Aktiebolaget Astra Unit dose container
CA2027690A1 (en) 1990-10-18 1992-04-19 Christian Laing Plastic ampul
FR2687066A1 (fr) 1992-02-06 1993-08-13 Oreal Ampoule autocassable.
US5508269A (en) * 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US5758637A (en) * 1995-08-31 1998-06-02 Aerogen, Inc. Liquid dispensing apparatus and methods
US6083922A (en) * 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
HUP0105226A3 (en) 1998-12-17 2003-03-28 Pathogenesis Corp Seattle Method for the treatment of severe chronic bronchitis (bronchiectasis) with an aerosolized antibiotic
SE9902627D0 (sv) * 1999-07-08 1999-07-08 Siemens Elema Ab Medical nebulizer
DE19953317C1 (de) 1999-11-05 2001-02-01 Pari Gmbh Inhalationsvernebler
CA2447600C (en) 2001-05-18 2015-10-20 Chiron Corporation Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8715623B2 (en) 2001-12-19 2014-05-06 Novartis Ag Pulmonary delivery of aminoglycoside
US20080063606A1 (en) * 2001-12-19 2008-03-13 Tarara Thomas E Pulmonary delivery of aminoglycoside
US9421166B2 (en) 2001-12-19 2016-08-23 Novartis Ag Pulmonary delivery of aminoglycoside
US9200026B2 (en) 2003-03-10 2015-12-01 Merck Sharp & Dohme Corp. Antibacterial agents
US8664187B2 (en) 2004-06-18 2014-03-04 Novartis Ag Methods of treatment of endobronchial infections
US10131684B2 (en) 2007-10-25 2018-11-20 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
US9453042B2 (en) 2007-10-25 2016-09-27 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
US9669046B2 (en) 2008-10-24 2017-06-06 Cempra Pharmaceuticals, Inc. Biodefenses using triazole-containing macrolides
US20110195920A1 (en) * 2008-10-24 2011-08-11 Cempra Pharmaceuticals, Inc. Biodefenses using triazole-containing macrolides
US9072759B2 (en) 2008-10-24 2015-07-07 Cempra Pharmaceuticals, Inc. Biodefenses using triazole-containing macrolides
US9439918B2 (en) 2008-10-24 2016-09-13 Cempra Pharmaceuticals, Inc. Methods for treating gastrointestinal diseases
US9901592B2 (en) 2008-10-24 2018-02-27 Cempra Pharmaceuticals, Inc. Methods for treating resistant diseases using triazole containing macrolides
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
US9480679B2 (en) 2009-09-10 2016-11-01 Cempra Pharmaceuticals, Inc. Methods for treating malaria, tuberculosis and MAC diseases
US9051346B2 (en) 2010-05-20 2015-06-09 Cempra Pharmaceuticals, Inc. Process for preparing triazole-containing ketolide antibiotics
RU2597842C2 (ru) * 2010-07-12 2016-09-20 Кселлия Фармасьютикалз Апс Лечение легочных инфекций с помощью введения тобрамицина путем аэролизации
US9815863B2 (en) 2010-09-10 2017-11-14 Cempra Pharmaceuticals, Inc. Hydrogen bond forming fluoro ketolides for treating diseases
US10188674B2 (en) 2012-03-27 2019-01-29 Cempra Pharmaceuticals, Inc. Parenteral formulations for administering macrolide antibiotics
US10640536B2 (en) 2013-01-11 2020-05-05 Xellia Pharmaceuticals Aps Polymyxins, compositions, methods of making and methods of use
US9861616B2 (en) 2013-03-14 2018-01-09 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
WO2014152326A1 (en) * 2013-03-14 2014-09-25 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
US9751908B2 (en) 2013-03-15 2017-09-05 Cempra Pharmaceuticals, Inc. Convergent processes for preparing macrolide antibacterial agents
US10711040B2 (en) 2014-07-09 2020-07-14 Xellia Pharmaceuticals Aps Low substituted polymyxins and compositions thereof
US10532080B2 (en) 2014-10-03 2020-01-14 Xellia Pharmaceuticals Aps Sulfomethylated polymixin compositions
US11033602B2 (en) 2014-10-03 2021-06-15 Xellia Pharmaceuticals Aps Inhalation device
US10617703B2 (en) 2014-12-10 2020-04-14 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11278590B2 (en) 2015-08-05 2022-03-22 Cmpd Licensing, Llc Compositions and methods for treating nail infections
US11684567B2 (en) 2015-08-05 2023-06-27 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11690815B2 (en) 2015-08-05 2023-07-04 Cmpd Licensing Llc Hyperkeratotic skin condition treatments and compositions
US11793783B2 (en) 2015-08-05 2023-10-24 Cmpd Licensing, Llc Compositions and methods for treating an infection
US12029812B2 (en) 2015-08-05 2024-07-09 Cmpd Licensing, Llc Compositions and methods for treating an infection
US10898491B2 (en) 2015-12-18 2021-01-26 Cmpd Licensing, Llc Compositions and methods for treating an infection
US10898455B2 (en) 2016-01-07 2021-01-26 Cmpd Licensing, Llc Urea cream formulations
US10610503B2 (en) 2016-11-17 2020-04-07 Cmpd Licensing, Llc Compounded solutions of diclofenac and lidocaine and methods
US10525025B2 (en) 2016-11-17 2020-01-07 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
US9999604B2 (en) 2016-11-17 2018-06-19 Cmpd Licensing, Llc Compounded solutions of diclofenac and lidocaine and methods

Also Published As

Publication number Publication date
US20050207987A1 (en) 2005-09-22
US20120101055A1 (en) 2012-04-26
ES2261735T3 (es) 2006-11-16
EP1320355B1 (en) 2006-04-05
US20040265241A1 (en) 2004-12-30
PT1320355E (pt) 2006-08-31
DE60210402D1 (de) 2006-05-18
WO2002094217A1 (en) 2002-11-28
US6890907B2 (en) 2005-05-10
CA2447600C (en) 2015-10-20
DE60210402T2 (de) 2006-12-07
CA2447600A1 (en) 2002-11-28
EP1320355A1 (en) 2003-06-25
JP2009269923A (ja) 2009-11-19
AU2010210026A1 (en) 2010-09-02
US8507454B2 (en) 2013-08-13
DK1320355T3 (da) 2006-07-31
US20080095717A1 (en) 2008-04-24
ATE322249T1 (de) 2006-04-15
EP2186508A3 (en) 2010-08-25
US20040131555A1 (en) 2004-07-08
US20050201947A1 (en) 2005-09-15
US7825095B2 (en) 2010-11-02
US20110005518A1 (en) 2011-01-13
JP2004534763A (ja) 2004-11-18
EP2186508A2 (en) 2010-05-19

Similar Documents

Publication Publication Date Title
US7825095B2 (en) Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
US8664187B2 (en) Methods of treatment of endobronchial infections
Graham et al. No added benefit from nebulized amiloride in patients with cystic fibrosis
KR102012418B1 (ko) 에어로졸화에 의한 토브라마이신의 투여에 의한 폐 감염의 치료
CN102164487A (zh) 曲前列素的深肺部递送
Coates et al. Rapid pulmonary delivery of inhaled tobramycin for Pseudomonas infection in cystic fibrosis: a pilot project
AU2007202942B2 (en) Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
EP1598059A1 (en) Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
Coates et al. The challenges of quantitative measurement of lung deposition using 99mTc-DTPA from delivery systems with very different delivery times
AU2002339338A1 (en) Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
US20050175544A1 (en) Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION